Mitral valve regurgitation is the most common type of heart valve disease with an annual incidence of 250,000 newly diagnosed patients in the U.S. If left untreated, the disease can lead to pulmonary hypertension, arrhythmias, and congestive heart failure. Only around 50,000 people with mitral valve regurgitation undergo surgery each year because the traditional method of open heart surgery is too invasive and risky for the severity of the condition. The NeoChord DS1000 aims to change this by allowing for the first, minimally invasive mitral valve repair.
At Worrell, we worked with heart surgeons from the Mayo clinic to take a proof-of-concept prototype and develop it into an ergonomic, manufacturable instrument.
The DS1000 consists of four parts: a handle probe, an interface confirming capture of the valve, a needle to deploy a suture, and a cartridge containing a single suture.
To repair the prolapsing mitral valve, the surgeon advances a needled that captures and pulls a suture through the valve.